Drugs News and Research

RSS

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University's Kimmel Cancer Center.

11 Dec 2013

New drug combination therapy effective for patients with HER2-positive breast cancer

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

11 Dec 2013

First patient enrolled in Otonomy's pivotal Phase 2b study of OTO-104 for Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced enrollment of the first patient in its pivotal Phase 2b study of OTO-104 for the reduction of vertigo in patients with unilateral Meniere's disease.

11 Dec 2013

AlzeCure deploys Vortex tool to develop novel therapies for Alzheimer's disease

Dotmatics, a leading provider of scientific informatics solutions and services to the pharmaceutical and biotechnology industries, announced today that the research foundation AlzeCure, has deployed and integrated the data visualization and analysis tool Vortex. AlzeCure is a novel innovative drug discovery unit that will use Vortex to help in the quest to discover and develop novel therapies for the treatment of Alzheimer's disease and other neurodegenerative disorders.

11 Dec 2013

Elsevier's Gold Standard drug database first to include CMS' NADAC price type

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today that, effective November 30, 2013, the Centers for Medicare & Medicaid Services' (CMS) survey-based price type, National Average Drug Acquisition Cost (NADAC) is included for all available drugs where applicable in Elsevier's Gold Standard Drug Database and web-based solutions, ProspectoRx and RxPrice Verify.

11 Dec 2013

Valuable new approach to cancer treatment

Since the discovery of penicillin, fungi have been a nearly inexhaustible source for the discovery of new drugs. “Crowdsourcing”, the cooperation of a large number of interested nonscientists, has helped to find a new fungus from which American researchers have now isolated and characterized an unusual metabolite with interesting antitumor activity.

11 Dec 2013

EPSRC donates £5 million for dementia research

Health ministers from the G8 nations will meet in London today (11 December) to discuss the global health challenge posed by dementia. The summit aims to develop co-ordinated global action on dementia. One area of focus at the summit is preventing and delaying dementia.

11 Dec 2013

New family of drugs may help combat childhood tumor

St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project study identifies drugs that enhance oxidative stress as possible weapon against most common pediatric soft tissue tumor

11 Dec 2013

Viewpoints: Health law problems plague Calif. too; Obamacare redistribution is from lucky to unlucky; FDA crackdown on genetic testing

While politicians in Washington are hailing California's exchange as proof of the law's success, voters in California don't seem to agree - and it's not hard to understand why. Policies for about 900,000 Californians are being cancelled because they don't meet the law's benefit mandates.

11 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Researchers personalizing cancer treatments for young patients

The aim of personalizing cancer treatments by targeting genomic mutations in the cancer has seen rapid advances in recent years. However, many of these targeted cancer therapies have been more frequently identified for adult patients. Recognizing a need to further explore genomic profiling in pediatric malignancies, the Hugs for Brady Foundation has committed $300,000 to the precision medicine initiative at Rutgers Cancer Institute of New Jersey.

11 Dec 2013

Acid-inhibiting medications linked with increased risk for vitamin B12 deficiency

Use for 2 or more years of proton pump inhibitors and histamine 2 receptor antagonists (two types of acid-inhibiting medications) was associated with a subsequent new diagnosis of vitamin B12 deficiency, according to a study appearing in the December 11 issue of JAMA.

11 Dec 2013

New research reveals novel way to develop anti-diarrhoeal drugs

New gastroenterology research carried out by the RCSI in conjunction with Trinity College Dublin and Johns Hopkins University in Baltimore, Maryland has uncovered a new route for the development of anti-diarrhoeal drugs.

11 Dec 2013

Budget cuts, years-long flat funding can delay research into effective treatments for cancer

Research advances that have come to fruition over the past year demonstrate extraordinary progress in the fight against cancer, according to a new report released today by the American Society of Clinical Oncology. The report stresses, however, that recent budget cuts and years-long flat funding can only delay efforts to translate research into effective treatments for millions of individuals with cancer.

11 Dec 2013

Exercise at the right time improves sexual functioning in women who take antidepressants

New psychology research, which could have important public health implications for alleviating some side effects of antidepressants, shows that engaging in exercise at the right time significantly improves sexual functioning in women who are taking the antidepressants.

11 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

High cholesterol fuels growth and spread of breast Cancer

Researchers at Duke Medicine conclude that high cholesterol may make breast cancer worse when they found that a byproduct of cholesterol functions like the hormone estrogen, leading to increases in the growth and spread of breast cancer. Studies have previously shown the link between obesity and breast cancer, but the exact cause of the increased risk had not been identified.

11 Dec 2013

Genzyme granted Priority Review for Cerdelga investigational oral therapy for Gaucher disease

Genzyme, a Sanofi company, announced today that the Food and Drug Administration (FDA) has granted a six-month Priority Review designation to its New Drug Application (NDA) for Cerdelga™ (eliglustat), an investigational oral therapy for adult patients with Gaucher disease type 1.

11 Dec 2013

CPAP treatment effective in patients with obstructive sleep apnea and hypertension

Among patients with obstructive sleep apnea and hypertension that requires 3 or more medications to control, continuous positive airway pressure treatment for 12 weeks resulted in a decrease in 24-hour average and diastolic blood pressure and an improvement in the nocturnal blood pressure pattern, compared to patients who did not receive CPAP, according to a study appearing in the December 11issue of JAMA.

11 Dec 2013

Acetylon Pharmaceuticals presents positive preclinical data for selective HDAC1/2 inhibitors at ASH meeting

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, announced that positive preclinical data for its selective HDAC1/2 inhibitors for the treatment of sickle cell disease (SCD) and β-thalassemia (bT) were presented at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA.

11 Dec 2013

Drugs News and Research

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

New drug combination therapy effective for patients with HER2-positive breast cancer

First patient enrolled in Otonomy's pivotal Phase 2b study of OTO-104 for Meniere's disease

AlzeCure deploys Vortex tool to develop novel therapies for Alzheimer's disease

Elsevier's Gold Standard drug database first to include CMS' NADAC price type

Valuable new approach to cancer treatment

EPSRC donates £5 million for dementia research

New family of drugs may help combat childhood tumor

Viewpoints: Health law problems plague Calif. too; Obamacare redistribution is from lucky to unlucky; FDA crackdown on genetic testing

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Researchers personalizing cancer treatments for young patients

Acid-inhibiting medications linked with increased risk for vitamin B12 deficiency

New research reveals novel way to develop anti-diarrhoeal drugs

Budget cuts, years-long flat funding can delay research into effective treatments for cancer

Exercise at the right time improves sexual functioning in women who take antidepressants

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

High cholesterol fuels growth and spread of breast Cancer

Genzyme granted Priority Review for Cerdelga investigational oral therapy for Gaucher disease

CPAP treatment effective in patients with obstructive sleep apnea and hypertension

Acetylon Pharmaceuticals presents positive preclinical data for selective HDAC1/2 inhibitors at ASH meeting

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News